In: Friedman H, Yamamoto Y, Bendinelli M, eds. Chlamydia pneumoniae Infection and Disease. New York: Kluwer Academic/Plenum Publishers, 2004; 239-262***
Most comprehensive review to date discussing the role of C. pneumoniae in asthma, lung remodeling and COPD. Disease burden and societal costs of asthma and COPD are conventionally calculated as separate entities. If early treatment of C. pneumoniae (and/or other pathogens) benefits both asthma (by symptom control) and COPD (by interrupting pathogenesis), then benefit/cost ratios increase, perhaps dramatically.
PDF NOT WORKING AT THIS TIME